Key result
Systemic lupus erythematosus patients with metabolic syndrome had higher aortic pulse wave velocity and increased biomarkers of subclinical atherosclerosis compared to those without metabolic syndrome.
Why the study?
Does metabolic syndrome increase arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus?
Cross-Sectional (n=128)
No
Does metabolic syndrome increase arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus?
Metabolic syndrome is independently associated with increased arterial stiffness and subclinical atherosclerosis biomarkers in patients with systemic lupus erythematosus, suggesting it contributes to accelerated atherosclerosis in this population.
Answers are grounded in this paper and cite their sources.
Metabolic syndrome may identify higher vascular risk in SLE; hypothesis-generating and requires prospective trials before practice change.
OBJECTIVE: Aortic pulse wave velocity (PWV) is an independent predictor of risk for atherosclerotic cardiovascular disease. Metabolic syndrome (MetS) is more prevalent in patients with systemic lupus erythematosus (SLE) compared with matched healthy subjects. Aortic PWV is increased in MetS. The purpose of this cross-sectional study was to determine the association between MetS and aortic PWV and other surrogate biomarkers of subclinical atherosclerosis in SLE. METHODS: One hundred twenty-eight patients with SLE were studied. We established the presence of MetS according to the National Cholesterol Education Program Adult Treatment Panel III definition and we measured PWV, glucose, insulin, glycosylated hemoglobin (HbA(1c)), insulin sensitivity (HOMA index), lipid levels, uric acid, homocysteine, fibrinogen, D-dimer, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), interleukin 6 (IL-6), IL-8, IL-10, C3, C4, autoantibodies, SLE Disease Activity Index (SLEDAI), and Systemic Lupus International Collaborating Clinics/ACR Damage Index. Duration of SLE and treatment was also recorded. Multivariate logistic regression analysis was used to identify independent determinants of increased PWV. RESULTS: SLE patients with MetS had higher aortic PWV (9.8 +/- 2.4 vs 8.5 +/- 1.7 m/s; p = 0.002) and increased biomarkers of subclinical atherosclerosis such as CRP, IL-6, C3, uric acid, homocysteine, fibrinogen and D-dimer, compared to those without MetS. HOMA index and insulin and HbA(1c) levels were also higher in this group. No differences were found in variables related to lupus activity (ESR, C4, SLEDAI, IL-8, IL-10, and treatment for SLE). In the multivariate model, increased PWV was associated with age, male sex, MetS, duration of SLE, and CRP. CONCLUSION: MetS may contribute to the development of accelerated atherosclerosis in SLE.
No takes yet. Share an insight, caveat, or question.
Sabio et al. (2009) conducted a cross-sectional in Systemic Lupus Erythematosus (n=128). Metabolic syndrome vs. No metabolic syndrome was evaluated on Aortic pulse wave velocity (PWV) (p=0.002). Systemic lupus erythematosus patients with metabolic syndrome had higher aortic pulse wave velocity and increased biomarkers of subclinical atherosclerosis compared to those without metabolic syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: